RxDoctor Payments Data

Karen Bean, NP

Nurse Practitioner · Caldwell, IDNPI 1326132432

Payments from drug & device makers

$609in general payments, 2019–2025

Across 36 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$206
  • AstraZeneca$105
  • Lilly USA, LLC$60
  • Exact Sciences$47
  • AbbVie$40
  • Xeris Pharmaceuticals, Inc.$40
  • plus $111 from 6 others

What the payments were for

  • Food & beverage$609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$609 in reported general payments places this provider in the 70th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$27,781
Medicare patients
116
Services billed
565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$57,898
EliquisApixaban52$49,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$45,179
FarxigaDapagliflozin Propanediol31$30,428
TrulicityDulaglutide31$29,385
Tresiba Flextouch U-200Insulin Degludec22$24,487
RybelsusSemaglutide25$23,074
JardianceEmpagliflozin18$17,623
CreonLipase/Protease/Amylase12$16,719
Nurtec OdtRimegepant Sulfate12$13,554
MounjaroTirzepatide12$12,264
Breo ElliptaFluticasone/Vilanterol17$6,477
MyrbetriqMirabegron13$5,616
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen135$4,769
Celecoxib96$4,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$206$80,97268 claims
GSKTrelegy Ellipta, Breo Ellipta$21$51,65675 claims
Lilly USA, LLCTrulicity, Mounjaro$60$41,64943 claims
AstraZenecaFarxiga$105$30,42831 claims
AbbVieCreon$40$16,71912 claims
Astellas Pharma US IncMyrbetriq$16$5,61613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Caldwell

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →